Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

Rhea-AI Summary

Oncotelic Therapeutics (OTCQB:OTLC) announced that CEO Dr. Vuong Trieu will deliver a keynote presentation on their innovative Deciparticles™ platform at the IDDST-Europe Conference in Stockholm, June 18-20, 2025.

Deciparticles represent a breakthrough in drug delivery technology as sub-20 nm nanoparticles designed to overcome challenges in delivering insoluble drugs to solid tumors. The platform has demonstrated success in formulating over 90% of tested water-insoluble drugs, including taxanes.

Key highlights include:

• Enhanced tumor penetration and superior antitumor efficacy compared to conventional formulations
• Integration of biomarker-driven strategies using DNA methylation signatures
• Lead candidate Sapu-001 showing promising preclinical results with higher maximum-tolerated dose and reduced toxicity

The presentation is scheduled for June 19, 2025, at 10:30 CET, with Phase 1 clinical trials for Sapu-001 anticipated later in 2025.

AGOURA HILLS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC), a biotechnology company focused on nanomedicine and RNA-based therapeutics, announced today that its Chairman and CEO, Dr. Vuong Trieu, will deliver a keynote presentation at the 21st Annual Congress of International Drug Discovery Science & Technology (IDDST-Europe), scheduled for June 18-20, 2025, in Stockholm, Sweden.

Dr. Trieu's presentation, titled " Deciparticles: Novel Sub-20 nm Nanoparticles for Advanced Drug Delivery" will highlight the groundbreaking Deciparticles™ platform developed by Oncotelic Therapeutics and Sapu Nano. Deciparticles are a novel class of sub-20 nm nanoparticles specifically engineered to overcome challenges associated with delivering insoluble drugs to solid tumors. Deciparticles platform is able to formulate more than 90% of all water insoluble drugs tested – including the taxanes,

The presentation will outline key findings demonstrating that Deciparticles significantly improve tumor penetration and achieve superior antitumor efficacy compared to conventional formulations. A central feature of this innovation is the integration of biomarker-driven strategies, leveraging DNA methylation signatures and gene-expression profiles predictive of patient survival, potentially enabling personalized therapeutic interventions. Oncotelic's lead candidate, Sapu-001, has shown promising preclinical results, demonstrating a higher maximum-tolerated dose and reduced toxicity relative to existing therapies.

Dr. Trieu emphasized, "With Deciparticles, we've entered a new era of targeted drug delivery—leveraging sub-20 nm nanoparticles combined with epigenetic biomarkers to significantly enhance treatment outcomes for patients. We anticipate Phase 1 clinical trials for Sapu-001 later this year."

Presentation Details:

Event: IDDST-Europe 2025 Conference
Date: June 19, 2025, at 10:30 CET
Speaker: Vuong Trieu, Ph.D., Chairman & CEO, Oncotelic Therapeutics
Title: " Deciparticles: Novel Sub-20 nm Nanoparticles for Advanced Drug Delivery"

About Oncotelic

Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (“AML” through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our 2023 Annual Report on form 10-K filed with the SEC on April 12, 2024.

Oncotelic's Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration statement and approval of the PDAO, or any other tokens that we may launch, as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 12, 2024 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.

Contact Information:

For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com

FAQ

What are Deciparticles and how do they improve cancer treatment according to OTLC's latest announcement?

Deciparticles are sub-20 nm nanoparticles that improve delivery of insoluble drugs to solid tumors, with capability to formulate over 90% of water-insoluble drugs, including taxanes, offering enhanced tumor penetration and superior antitumor efficacy.

When will Oncotelic (OTLC) begin Phase 1 trials for Sapu-001?

According to the announcement, Oncotelic plans to begin Phase 1 clinical trials for Sapu-001 later in 2025.

What advantages does OTLC's Sapu-001 show in preclinical studies?

Sapu-001 has demonstrated a higher maximum-tolerated dose and reduced toxicity compared to existing therapies in preclinical studies.

How does OTLC's Deciparticles platform utilize biomarkers for cancer treatment?

The platform integrates biomarker-driven strategies, using DNA methylation signatures and gene-expression profiles that predict patient survival, enabling potential personalized therapeutic interventions.

When and where will OTLC present their Deciparticles technology in 2025?

Dr. Vuong Trieu will present the Deciparticles technology at the IDDST-Europe Conference in Stockholm on June 19, 2025, at 10:30 CET.